These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30875344)

  • 1. CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
    Zhu Y; Zhang N; Ren D; Bi Y; Xu F; Niu W; Sun Q; Guo Z; Yuan R; Yuan F; Wu X; Cao Y; Yang F; Wang L; Du L; Li W; Xu Y; Li X; Zhu L; He L; Shi L; He G; Yu T
    Clin Neuropharmacol; 2019; 42(2):32-36. PubMed ID: 30875344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
    Zhang N; Ji L; Chen Z; An L; Ren D; Bi Y; Guo Z; Yuan R; Yuan F; Dong Z; Yin L; Sun X; Yang F; Li X; Yu T; He L; Shi L; He G
    Psychiatr Genet; 2020 Feb; 30(1):30-33. PubMed ID: 31842058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
    Yeh YW; Chen CJ; Jang FL; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Shyu JF; Wan FJ; Lu RB; Huang SY
    J Psychiatr Res; 2015 Feb; 61():33-9. PubMed ID: 25512257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients.
    Wu N; Liu L; Ren D; Yuan F; Bi Y; Guo Z; Hou B; Ji L; Han K; Feng M; Su K; Yu T; Li X; Yang F; Sun X; Dong Z; Yu S; Yi Z; Xu Y; He L; Wu S; Zhao L; Changqun C; Shi Y; He G
    Clin Neuropharmacol; 2021 Mar-Apr 01; 44(2):53-56. PubMed ID: 33480616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.
    Lin KM; Tsou HH; Tsai IJ; Hsiao MC; Hsiao CF; Liu CY; Shen WW; Tang HS; Fang CK; Wu CS; Lu SC; Kuo HW; Liu SC; Chan HW; Hsu YT; Tian JN; Liu YL
    Pharmacogenomics; 2010 Nov; 11(11):1535-43. PubMed ID: 21121774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.
    Sun Q; Yuan F; Yuan R; Ren D; Zhu Y; Bi Y; Hu J; Guo Z; Xu F; Niu W; Ma G; Wu X; Yang F; Wang L; Li X; Yu T; He L; He G
    Medicine (Baltimore); 2019 May; 98(19):e15456. PubMed ID: 31083176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients.
    Zou YF; Wang Y; Liu P; Feng XL; Wang BY; Zang TH; Yu X; Wei J; Liu ZC; Liu Y; Tao M; Li HC; Li KQ; Hu J; Li M; Zhang KR; Ye DQ; Xu XP
    Neuropsychobiology; 2010; 61(2):71-8. PubMed ID: 20016225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.
    Yuan F; Yuan R; Ren D; Bi Y; Niu W; Guo Z; Wu X; Xu F; Sun Q; Ma G; Yang F; Zhu Y; Yu T; Li X; He L; Shi L; He G
    Psychiatry Res; 2020 Feb; 284():112690. PubMed ID: 31757642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
    Ng C; Sarris J; Singh A; Bousman C; Byron K; Peh LH; Smith DJ; Tan CH; Schweitzer I
    Hum Psychopharmacol; 2013 Sep; 28(5):516-22. PubMed ID: 24014145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychomotor depressive symptoms may differentially respond to venlafaxine.
    Singh AB; Bousman CA; Ng CH; Byron K; Berk M
    Int Clin Psychopharmacol; 2013 May; 28(3):121-6. PubMed ID: 23442739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.
    Wang P; Lv Q; Mao Y; Zhang C; Bao C; Sun H; Chen H; Yi Z; Cai W; Fang Y
    J Affect Disord; 2018 Mar; 228():222-228. PubMed ID: 29275155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
    Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harm avoidance involved in mediating the association between nerve growth factor (NGF) gene polymorphisms and antidepressant efficacy in patients with major depressive disorder.
    Yeh YW; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Chen TY; Shyu JF; Wan FJ; Lu RB; Huang SY
    J Affect Disord; 2015 Sep; 183():187-94. PubMed ID: 26021968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
    Marshe VS; Maciukiewicz M; Rej S; Tiwari AK; Sibille E; Blumberger DM; Karp JF; Lenze EJ; Reynolds CF; Kennedy JL; Mulsant BH; Müller DJ
    Am J Psychiatry; 2017 May; 174(5):468-475. PubMed ID: 28068779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis.
    Kato M; Asami Y; Wajsbrot DB; Wang X; Boucher M; Prieto R; Pappadopulos E
    J Psychiatr Res; 2020 Oct; 129():160-167. PubMed ID: 32912597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
    Wang HC; Yeh TL; Chang HH; Gean PW; Chi MH; Yang YK; Lu RB; Chen PS
    Psychopharmacology (Berl); 2011 Feb; 213(4):773-9. PubMed ID: 20945066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.